 with signiﬁcant functional or
lifestyle-limiting disability when there is a reasonable likelihood of symptomatic improvement
with treatment, when pharmacologic or exercise therapy, or both, have failed, and when the
beneﬁts of treatment outweigh the potential risks.
We recommend an individualized approach to select an invasive treatment for IC. The modality
offered should provide a reasonable likelihood of sustained beneﬁt to the patient (>50%
likelihood of clinical efﬁcacy for